PRL and prostate carcinoma: Finally, Bioinformatics analysis showed that compared to control group, the metabolic pathways with significant differences in WAS group were as follows: endocrine resistance, tryptophan metabolism, prostate cancer and prolactin signaling pathway (Figure 9A and Table 1).